Eris Lifesciences has entered into definitive agreements with Strides Shasun for acquisition of Strides’ branded generics business in India for an aggregate cash consideration of Rs 500 crore. In terms of the agreement, Eris will acquire the marketing and distribution rights for the said portfolio of products in India while Strides will retain the global rights for these products.
With this acquisition, Eris’s will be among the top ten companies in the Central Nervous System (CNS) segment. Eris is already among the top 20 companies in the cardiology segment and ranks among the top ten in the diabetology segment.
Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1530.00 |
Dr. Reddys Lab | 5802.00 |
Cipla | 1399.35 |
Zydus Lifesciences | 1051.90 |
Lupin | 1653.75 |
View more.. |